Catabasis Pharmaceuticals (NASDAQ:CATB) posted its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.07, Yahoo Finance reports. The business had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.25 million.
NASDAQ:CATB traded up $0.01 during mid-day trading on Friday, hitting $1.77. The stock had a trading volume of 101,316 shares, compared to its average volume of 335,300. The company has a market cap of $51.39, a PE ratio of -1.40 and a beta of 0.69. Catabasis Pharmaceuticals has a 52 week low of $1.09 and a 52 week high of $3.78.
Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research report on Tuesday, March 20th. Wedbush lifted their price objective on shares of Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Tuesday, March 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Catabasis Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $5.18.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/catabasis-pharmaceuticals-catb-issues-earnings-results.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.